Table 1.
Pharmacokinetic characteristics of nemonoxacin in 12 healthy Chinese volunteers after a single oral dose of 500 mg of nemonoxacin alone or with probenecid
| Parameters | Nemonoxacin alone (Treatment A) | Nemonoxacin with probenecid (Treatment B) | Geometric mean ratio (B:A)a |
|---|---|---|---|
| AUC0−t, h·μg/mL | 46.3 (7.4) | 58.7 (11.5) | 1.25 (1.19–1.32) |
| AUC0−∞, h·μg/mL | 46.5 (7.5) | 58.4 (11.5) | 1.25 (1.19–1.32) |
| Cmax, μg/mL | 5.67 (7.04) | 5.76 (1.04) | 1.01 (0.96–1.06) |
| tmax, h | 1 (0.67–3.0)b | 1.5 (0.67–4.0)b | – |
| t1/2, h | 9.76 (0.74) | 9.62 (0.74) | – |
| MRT, h | 9.24 (0.51) | 11.1 (0.9) | – |
| CL/F, L/h | 11.0 (1.8) | 8.83 (1.77) | – |
| Vz/F, L | 155 (31) | 123 (31) | – |
| Fe, % | 58.2 (9.4) | 56.5 (7.1) | 0.96 (0.88–1.03) |
| CLr, L/h | 6.41 (1.85) | 4.96 (1.10) | 0.76 (0.71–0.82) |
Note: Data are mean (standard deviations), except
point estimates (90% confidence intervals) and
medians (ranges). The dash indicates no data available.
Abbreviations: AUC0−∞, area under the plasma concentration–time curve from time 0 to infinity; AUC0−t, area under the plasma concentration time curve from time 0 to the last time point; Cmax, maximum concentration; CL/F, oral clearance; CLr, renal clearance; Fe, percentage of the administered dose recovered in the urine; MRT, mean residence time; t1/2, terminal elimination half-life; tmax, time to reach Cmax; Vz/F, terminal volume of distribution without correction for bioavailability.